The suppression of p53 and p73 activity by the upregulated MDMX in cancer cells has been the target of drug development for retinoblastoma, pancreatic cancer, colorectal cancer, and breast cancer therapy, yet no MDMX antagonist has been approved for clinical application 18-20. This evidence concerns the gene MDM4 and breast cancer.